Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2007 2
2008 1
2010 1
2014 1
2015 1
2016 1
2017 1
2018 2
2019 3
2020 3
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

17 results
Results by year
Filters applied: . Clear all
Page 1
Disruption of IRE1α through its kinase domain attenuates multiple myeloma.
Harnoss JM, Le Thomas A, Shemorry A, Marsters SA, Lawrence DA, Lu M, Chen YA, Qing J, Totpal K, Kan D, Segal E, Merchant M, Reichelt M, Ackerly Wallweber H, Wang W, Clark K, Kaufman S, Beresini MH, Laing ST, Sandoval W, Lorenzo M, Wu J, Ly J, De Bruyn T, Heidersbach A, Haley B, Gogineni A, Weimer RM, Lee D, Braun MG, Rudolph J, VanWyngarden MJ, Sherbenou DW, Gomez-Bougie P, Amiot M, Acosta-Alvear D, Walter P, Ashkenazi A. Harnoss JM, et al. Among authors: sherbenou dw. Proc Natl Acad Sci U S A. 2019 Aug 13;116(33):16420-16429. doi: 10.1073/pnas.1906999116. Epub 2019 Aug 1. Proc Natl Acad Sci U S A. 2019. PMID: 31371506 Free PMC article.
Potent Activity of an Anti-ICAM1 Antibody-Drug Conjugate against Multiple Myeloma.
Sherbenou DW, Su Y, Behrens CR, Aftab BT, Perez de Acha O, Murnane M, Bearrows SC, Hann BC, Wolf JL, Martin TG, Liu B. Sherbenou DW, et al. Clin Cancer Res. 2020 Nov 15;26(22):6028-6038. doi: 10.1158/1078-0432.CCR-20-0400. Epub 2020 Sep 11. Clin Cancer Res. 2020. PMID: 32917735 Free PMC article.
Phase II study of carfilzomib and dexamethasone therapy for newly diagnosed multiple myeloma.
Forsberg PA, Rossi AC, Boyer A, Tegnestam L, Pearse RN, Perry A, Pekle KA, Jayabalan D, Ely S, Boussi L, Sherbenou DW, Williams C, Allan JN, Coleman M, Niesvizky R, Mark TM. Forsberg PA, et al. Among authors: sherbenou dw. Am J Hematol. 2019 May;94(5):539-545. doi: 10.1002/ajh.25435. Epub 2019 Feb 25. Am J Hematol. 2019. PMID: 30740766 Free article. Clinical Trial.
Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer.
Su Y, Liu Y, Behrens CR, Bidlingmaier S, Lee NK, Aggarwal R, Sherbenou DW, Burlingame AL, Hann BC, Simko JP, Premasekharan G, Paris PL, Shuman MA, Seo Y, Small EJ, Liu B. Su Y, et al. Among authors: sherbenou dw. JCI Insight. 2018 Sep 6;3(17):e121497. doi: 10.1172/jci.insight.121497. eCollection 2018 Sep 6. JCI Insight. 2018. PMID: 30185663 Free PMC article.
17 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page